Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Archive | Research

Tags: , , ,

Kyprolis effective for some patients that have used Velcade

Posted on February 02 2016 by Pat Killingsworth

MedPage Today reported on a new, retrospective study involving Kyprolis over the weekend. It makes my myeloma specialist, Dr. Tricot, look pretty smart for using Kyprolis as part of my three drug post transplant consolidation therapy.

Comments (0)

MT K

Tags: , ,

Isn’t battling myeloma hard enough without having to raise money, too?

Posted on January 27 2016 by Pat Killingsworth

An amazing over-the-top (pun intended) multiple myeloma awareness and fundraising mountain climbing adventure scaling Mr. Kilimanjaro sponsored by the MMRF:

Comments (4)

MMRF 2015 myeloma year in review

Tags: , ,

MMRF 2015 myeloma year in review

Posted on January 21 2016 by Pat Killingsworth

I’m part of a Cure Talk Radio broadcast in a few hours featuring Multiple Myeloma Research Foundation co-founder, Anne Quinn Young. If you can’t listen live, I’ll pass along a link so you an listen later.

Comments (1)

Blood Glucose, MGUS, Myeloma & Metformin (Part Nine)

Blood Glucose, MGUS, Myeloma & Metformin (Part Nine)

Posted on January 16 2016 by Pat Killingsworth

A lot has happened since I ran two of the final installments about the importance of controlling blood glucose by Danny Parker:

Comments (1)

powerball

Tags: ,

Could almost a billion dollars cure multiple myeloma?

Posted on January 13 2016 by Pat Killingsworth

How much money would it take to cure multiple myeloma? 50 million? 100 million? With some off-the-charts luck, we’ll know in just over an hour. For the first time ever, I’m playing Powerball. The one time payout on the 1.5 billion dollar jackpot: 930 million dollars.

Comments (12)

Jenny’s family

Tags: , , , ,

Wall Street Journal article about myeloma hits a home run

Posted on January 06 2016 by Pat Killingsworth

Monday morning my email inbox lit up. A Wall Street Journal article–both online and in the hard copy edition–about the FDA’s unprecedented approval of three anti-myeloma drugs in less than a month was featured front and center.

Comments (2)

The power of combination therapies

Tags: , , ,

The power of combination therapies

Posted on January 02 2016 by Pat Killingsworth

New checkpoint inhibitor studies combining the experimental drug, Keytruda, with Revlimid, are working in patients who have become refractory to Revlimid.

Comments (4)

Key research breakthroughs at ASH

Tags: ,

Key research breakthroughs at ASH

Posted on December 29 2015 by Pat Killingsworth

Did you see the MMRF’s outline of important myeloma related news at ASH this year? Short and to the point.

Comments (0)

Merck

Tags: , , ,

Hopeful news about first PD-1 inhibitor

Posted on December 22 2015 by Pat Killingsworth

Another exciting, new immunotherapy may be on the horizon: Keytruda

Comments (2)

Dr. Rajkumar

Tags: , , ,

Blood Glucose, MGUS, Myeloma & Metformin (Part Seven and Eight)

Posted on December 20 2015 by Pat Killingsworth

ASH, unscheduled trips to the ICU, Iowa City drama. A lot has happened since I ran the last installment of Danny Parker’s series about blood glucose and metformin.

Comments (3)

Ahmadi-Tahamtan

Tags: , , , ,

Inside look at Darzalex (daratumumab)

Posted on December 17 2015 by Pat Killingsworth

Last week I had the opportunity to interview the Senior Director of Clinical Research for Janssen Pharmaceuticals, Dr. Tahamtan Ahmadi, PhD. Janssen is the company that manufacturers newly FDA approved Darzalex (daratumumab). I promised a more detailed follow up and I’m glad to follow through.

Comments (3)

Back to ASH: Ninlaro and Pomalyst combo promising

Tags: , , ,

Back to ASH: Ninlaro and Pomalyst combo promising

Posted on December 14 2015 by Pat Killingsworth

Before I pass along important information about Takeda’s new oral proteasome inhibitor, Ninlaro (ixazomib), I wanted to share an update about how I’m doing.

Comments (0)

More drugs are good, but aren’t enough

Tags: , , , , ,

More drugs are good, but aren’t enough

Posted on December 08 2015 by Pat Killingsworth

Data for more than a dozen “new” myeloma drugs was presented at this week’s American Society of Hematology (ASH) meetings here in Orlando. As I described yesterday, several are hopeful crossover drugs; compounds that are already FDA approved for use against other cancers.

Comments (9)

abbvie logo

Tags: , , ,

Could leukemia and lymphoma drug work for myeloma patients, too?

Posted on December 08 2015 by Pat Killingsworth

I’m accumulating way too much information for me to process and pass along right away. I’m still waiting on company verified combination data for Darzalex/Pomalyst/dex. I’ll also have updated stats for ongoing elotuzumab and ARRY-520 trials. In the meantime, I interviewed Dr. Thorsten Graef, the Head of Hematology and Global Medical Safety for pharmacyclics, a California based company that produces the FDA approved leukemia drug, Imbruvica (ibrutinib). The company is excited about the prospects that Imbruvica can work against multiple myeloma, too.

Comments (3)

janssen logo

Tags: , , ,

BREAKING NEWS: Early data featuring Darzalex in combination with Revlimid

Posted on December 07 2015 by Pat Killingsworth

As promised, here are details from a preliminary study showing impressive response rates when Darzalex (daratumumab) is combined with Revlimid and dexamethasone.

Comments (6)

Tags: , , , ,

Big news about daratumumab today

Posted on December 07 2015 by Pat Killingsworth

Happy Myeloma Monday! I’m not sure how or why the tradition began, but for the seven years I’ve been coming to ASH, Monday has always been the biggest myeloma news day.

Comments (10)

BREAKING NEWS: T cell therapy advances continue

Tags: , , ,

BREAKING NEWS: T cell therapy advances continue

Posted on December 06 2015 by Pat Killingsworth

I’m here at the American Society of Hematology (ASH) meetings in Orlando, helping CrowdCare Foundation founder, Jenny Ahlstrom. The big news here today focused on an impressive breakthrough in T cell therapy.

Comments (9)

Janssen

Tags: , ,

Has bad timing left ASH irrelevant?

Posted on December 04 2015 by Pat Killingsworth

I’m almost packed. Tomorrow I’ll be driving three hours south to Orlando to attend my 7th American Society of Hematology (ASH) annual meeting. Seven years! How the multiple myeloma therapy landscape has changed. Heck, things have been turned upside down in three short weeks.

Comments (2)

Pyramid

Tags: , ,

Blood Glucose, MGUS, Myeloma & Metformin (Part Six)

Posted on December 02 2015 by Pat Killingsworth

I wanted to squeeze in another of Danny Parker’s important columns before things get too busy right before ASH. He shifts gears, beginning to focus on clinical trials and the future of multiple myeloma¬† research.

Comments (6)

Tags: , , , , ,

More about elotuzumab (Empliciti). Are immunotherapies the answer?

Posted on December 01 2015 by Pat Killingsworth

In my haste to get the news out about elotuzumab’s FDA approval yesterday, I mistakenly relied on a Cure Magazine article that stated Kyprolis was the drug used in combination with elo. I was surprised, but ran with it. I should have known better. The Cure Magazine article was mistaken. Elotuzumab (Empliciti), Revlimid and dexamethasone is the correct combination. I apologize and I’ve corrected the post.

Comments (0)


Follow On Twitter!

Follow HelpWithMyeloma on Twitter

Archives